Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481832 · ClinicalTrials.gov registry record · Phase 2
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00481832: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00481832 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00481832, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this trial is to develop an alternative treatment for patients with poor risk non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem cell transplant using the patient's own cells. This is followed with non-myeloablative transplant using stem cells from a related or unrelated donor to try and generate an anti-lymphoma response from the new immune system.
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
- DRUG BCNU
- DRUG Filgrastim
- DRUG Antithymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-01 |
| Est. Completion | 2017-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00481832
The ClinicalTrials.gov registry entry for NCT00481832 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00481832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00481832 about?
NCT00481832 is a clinical study titled "Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma". The purpose of this trial is to develop an alternative treatment for patients with poor risk non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem cell transplant using the patient's own cells. This is followed with non-myeloablative transplant using stem cells fr...
What is the current status of trial NCT00481832?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-01. Estimated completion is 2017-03-30.
What interventions are being tested in trial NCT00481832?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG), BCNU (DRUG), Filgrastim (DRUG), Antithymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT00481832?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.